Antares Pharma Stock News

Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre

Antares Pharma Inc shares (NASDAQ: ATRS) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement Th

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing

Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO). The post Why Is Antares Pharma (ATRS) Stock Up Today?

Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes  appeared first on Penny Stocks to Buy, Picks, News and Info

The drug delivery specialist has reportedly agreed to a merger with Halozyme.

Shares of Antares Pharma Inc. ATRS, -0.27% rocketed 46.3% in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeu

Antares Pharma Inc (NASDAQ: ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript

Antares Pharma (NASDAQ: ATRS ) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Antares Pharma beat estimated earnings by 100.0%, reporting an EPS of $0.02 versus … Full story available on Benzinga.com

Antares Pharma press release (ATRS): Q4 Non-GAAP EPS of $0.02 beats by $0.01.Revenue of $48.73M (+10.5% Y/Y) beats by $1.54M.The Company today provided its full-year 2022…

Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million